Ulcerative Colitis Market Insight, Epidemiology And Market Forecast – 2034

The Ulcerative Colitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

DelveInsight’s “Ulcerative Colitis Market Insight, Epidemiology And Market Forecast – 2034″ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Ulcerative Colitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Visit, Ulcerative Colitis Market Insights

Some of the key facts of the Ulcerative Colitis Market Report:

• Ulcerative Colitis market size was highest in the United States among the 7MM countries

• September 2025

  • Eli Lilly’s Omvoh (mirikizumab-mrkz) received FDA approval for a single-injection, monthly maintenance regimen for adults with moderately to severely active UC, simplifying treatment.​

  • Pfizer’s Velsipity (etarsimod), an oral therapy developed after Pfizer’s acquisition of Arena Pharmaceuticals, was approved by the FDA, representing a significant advancement in UC management.

• October 2025

  • Eli Lilly’s mirikizumab received FDA approval for single-injection maintenance, building on its previous approvals for Crohn’s disease and other indications.​

  • Johnson & Johnson submitted an sBLA for Stelara (ustekinumab) to expand its approval for pediatric UC patients.

  • Merck & Co. completed its acquisition of Prometheus Biosciences for approximately USD 10.8 billion, aiming to leverage promising UC candidates like PRA023

• Ulcerative Colitis Companies: Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, NImmune, Merck, Mesoblast

• Ulcerative Colitis Therapies: Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, S1P modulators, Janus kinase inhibitors, Adalimumab, Infliximab, Golimumab, Ustekinumab, Mirikizumab, Vedolizumab, Ozanimod, Tofacitinib, Upadacitinib, Obefazimod (ABX464), Risankizumab, Guselkumab, Etrasimod, SHR0302 (Ivarmacitinib), Omilancor, SIMPONI (golimumab), ENTYVIO (vedolizumab), XELJANZ (tofacitinib), STELARA (ustekinumab), RINVOQ (upadacitinib), ZEPOSIA (ozanimod), REMICADE (infliximab), HUMIRA (adalimumab), SELARSDI (ustekinumab-aekn), STEQEYMA (ustekinumab-stba), YESINTEK (ustekinumab-kfce), AC-101 (RIPK2 inhibitor), and others.

Ulcerative Colitis Overview

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that causes inflammation and sores, or ulcers, in the inner lining of the large intestine and rectum. Common symptoms include bloody diarrhea, abdominal pain, cramping, and the urgent need for a bowel movement. While there is no cure, treatment focuses on managing symptoms and achieving remission through a combination of medication and, in severe cases, surgery.

Ulcerative Colitis Market

The dynamics of the Ulcerative Colitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2025-2034.

Ulcerative Colitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and the views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ulcerative Colitis Epidemiology Segmentation:

The Ulcerative Colitis market report offers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Ulcerative Colitis in the 7MM

• Age-specific Cases of Ulcerative Colitis in the 7MM

• Severity-specific Cases of Ulcerative Colitis in the 7MM

• Total Treated Patients of Ulcerative Colitis in the 7MM

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiological Insights

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Ulcerative Colitis treatment, visit @ Ulcerative Colitis Medications

Ulcerative Colitis Therapies and Key Companies

• SIMPONI (golimumab): Janssen Pharmaceuticals

• ENTYVIO (vedolizumab): Takeda Pharmaceuticals

• ZEPOSIA (ozanimod): Bristol Myers Squibb

• REMICADE (infliximab): Janssen Pharmaceuticals

• HUMIRA (adalimumab): AbbVie

• STELARA (ustekinumab): Janssen Pharmaceuticals

• RINVOQ (upadacitinib): AbbVie

• XELJANZ (tofacitinib): Pfizer

• ETRASIMOD: Arena Pharmaceuticals/Pfizer

• ABX464 (obefazimod): Abivax

• OMILANCOR: NImmune

• SHR0302 (Ivarmacitinib): Reistone Biopharma

• RISANKIZUMAB: AbbVie/Boehringer Ingelheim

• GUSELKUMAB: Janssen Pharmaceuticals

• AC-101 (RIPK2 inhibitor): Accropeutics Inc.

• SELARSDI (ustekinumab-aekn): Teva Pharmaceuticals/Alvotech

• STEQEYMA (ustekinumab-stba): Celltrion

• YESINTEK (ustekinumab-kfce): Biocon Biologics Ltd

Ulcerative Colitis Market Drivers

• Rising global prevalence of inflammatory bowel disease (IBD), including Ulcerative Colitis, particularly in developing regions.

• Growing adoption of biologics and novel targeted therapies, such as anti-TNFs, JAK inhibitors, and S1P modulators.

• Advancements in diagnostic tools and endoscopic imaging, enabling earlier and more accurate disease detection.

• Shift toward personalized medicine, with biomarkers and therapeutic drug monitoring guiding optimized treatment.

• Expansion of patient access to advanced therapies due to improving healthcare infrastructure and insurance coverage.

• High disease burden and chronicity, driving long-term treatment demand and continuous therapeutic innovation.

• Strong R&D pipeline, including next-generation biologics, oral small molecules, and microbiome-based therapies.

• Increased awareness and education among patients and clinicians, leading to earlier care-seeking and diagnosis.

• Regulatory support for innovative therapies, including expedited approvals for drugs addressing unmet needs.

• Growing focus on patient quality of life, increasing the need for effective, convenient, and steroid-sparing treatment options.

Ulcerative Colitis Market Barriers

• High cost of biologics and advanced therapies, limiting access and increasing payer scrutiny.

• Loss of response and treatment resistance, common with long-term use of anti-TNFs and other biologics.

• Safety concerns, including infection risk and adverse effects associated with immunosuppressive therapies.

• Delayed diagnosis, especially in regions with limited specialist access or low awareness of IBD.

• Heterogeneity in disease severity and progression, complicating treatment selection and clinical trial design.

• Intense market competition, with multiple biologics and small molecules targeting similar pathways.

• Reimbursement challenges for newer, high-cost therapies without clear superiority.

• Limited access to advanced care (endoscopy, biologics, therapeutic drug monitoring) in low- and middle-income regions.

• Patient adherence issues, particularly with chronic, long-term treatment regimens.

• Complex regulatory requirements for immunomodulatory and microbiome-based therapies.

Scope of the Ulcerative Colitis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

• Key Ulcerative Colitis Companies: Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, NImmune, Merck, Mesoblast

• Key Ulcerative Colitis Therapies: Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, S1P modulators, Janus kinase inhibitors, Adalimumab, Infliximab, Golimumab, Ustekinumab, Mirikizumab, Vedolizumab, Ozanimod, Tofacitinib, Upadacitinib, Obefazimod (ABX464), Risankizumab, Guselkumab, Etrasimod, SHR0302 (Ivarmacitinib), Omilancor, SIMPONI (golimumab), ENTYVIO (vedolizumab), XELJANZ (tofacitinib), STELARA (ustekinumab), RINVOQ (upadacitinib), ZEPOSIA (ozanimod), REMICADE (infliximab), HUMIRA (adalimumab), SELARSDI (ustekinumab-aekn), STEQEYMA (ustekinumab-stba), YESINTEK (ustekinumab-kfce), AC-101 (RIPK2 inhibitor) and others.

• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies

• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Ulcerative Colitis Unmet Needs, KOL’s views, Analyst’s views, Ulcerative Colitis Market Access and Reimbursement

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Landscape

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Ulcerative Colitis Market Overview at a Glance

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Ulcerative Colitis Background and Overview

8. Ulcerative Colitis Treatment

9. Ulcerative Colitis Epidemiology and Patient Population in the 7MM

10. Ulcerative Colitis Patient Journey

11. Ulcerative Colitis Marketed Drug

12. Ulcerative Colitis Emerging Drugs

13. Ulcerative Colitis: 7MM Analysis

14. Unmet needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services